Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Increased C-Reactive Protein Level Is Associated with Poor Prognosis in Patients with Follicular Lymphoma Treated with Rituximab-Containing Regimens

Yukiko Kawaguchi, MD, Bungo Saito, MD PhD, Yohei Sasaki, MD, Shotaro Shimada, MD, Megumi Watanuki, MD, Maasa Abe, MD, So Murai, MD, Yuta Baba, MD, Shun Fujiwara, MD, Nana Arai, MD, Nobuyuki Kabasawa, MD, Hiroyuki Tsukamoto, MDPhD, Yui Uto, MD PhD, Kouji Yanagisawa, MD, Norimichi Hattori, MD PhD, Eisuke Shiozawa, MD PhD, Masafumi Takimoto, MD PhD, Tsuyoshi Nakamaki, MD PhD

Blood (2017) 130 (Supplement 1): 4067.

https://doi.org/10.1182/blood.V130.Suppl_1.4067.4067

Published: 2017

Journal Articles

Differential Expression of IL-17 Correlates with Clinical and Pathological Features of ITP

Naoko Okamoto, MD, Mayumi Homma, MD PhD, Yukiko Kawaguchi, MD, Nobuyuki Kabasawa, MD, Yui Uto, MD PhD, Shohei Yamamoto, MD PhD, Norimichi Hattori, MD PhD, Eisuke Shiozawa, MD PhD, Toshiko Yamochi, MD PhD, Keiichi Isoyama, MD PhD, Tsuyoshi Nakamaki, MD PhD, Masafumi Takimoto, MD PhD

Blood (2017) 130 (Supplement 1): 3644.

https://doi.org/10.1182/blood.V130.Suppl_1.3644.3644

Published: 2017

Journal Articles

Immunohistochemical Expression of CD123 Is Associated with an Inferior Clinical Outcome in Acute Myeloid Leukemia

Nana Arai, MD, Bungo Saito, MD, Maasa Abe, MD, Megumi Watanuki, MD, So Murai, MD, Yuta Baba, MD, Yukiko Kawaguchi, MD, Shun Fujiwara, MD, Hiroyuki Tsukamoto, MD, Yui Uto, MD, Nobuyuki Kabasawa, MD, Kouji Yanagisawa, MD, Norimichi Hattori, MD, Mayumi Homma, MD, Eisuke Shiozawa, MD, Toshiko Yamochi, MD, Masafumi Takimoto, MD, Hiroshi Harada, MD, Tsuyoshi Nakamaki, MD

Blood (2016) 128 (22): 2887.

https://doi.org/10.1182/blood.V128.22.2887.2887

Published: 2016

Journal Articles

Scoring System Using Age, C-Reactive Protein, Hemoglobin, and Albumin (ACHA) For Predicting Outcomes Of Diffuse Large B-Cell Lymphoma In The Rituximab-Era

Hirotsugu Ariizumi, MD, Bungo Saito, MD, Eisuke Shiozawa, MD, Yui Uto, MD, Norimichi Hattori, MD, Kouji Yanagisawa, MD, Hidetoshi Nakashima, MD, Hiroshi Harada, MD, Hiraku Mori, MD, Tsuyoshi Nakamaki, MD

Blood (2013) 122 (21): 4305.

https://doi.org/10.1182/blood.V122.21.4305.4305

Published: 2013

Journal Articles

Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells

Tsuyoshi Nakamaki, MD, Kunihiko Fukuchi, MD, Hidetoshi Nakashima, MD, Hirotsugu Ariizumi, MD, Takashi Maeda, MD, Bungo Saito, MD, Kouji Yanagisawa, MD, Shigeru Tomoyasu, MD, Eisuke Shiozawa, MD, Toshiko Yamochi-Onizuka, MD, Hidekazu Ota, MD

Blood (2011) 118 (21): 2421.

https://doi.org/10.1182/blood.V118.21.2421.2421

Published: 2011

Journal Articles

Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

Bungo Saito, MD, Eisuke Shiozawa, M.D, Takako Usui, M.D, Hidetoshi Nakashima, M.D, Takashi Maeda, M.D, Norimichi Hattori, M.D, Daisuke Adachi, M.D, Toshiko Yamochi-Onizuka, M.D, Masafumi Takimoto, M.D, Tsuyoshi Nakamaki, M.D, Hidekazu Ota, M.D, Shigeru Tomoyasu, M.D

Blood (2006) 108 (11): 2032.

https://doi.org/10.1182/blood.V108.11.2032.2032

Published: 2006

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Increased C-Reactive Protein Level Is Associated with Poor Prognosis in Patients with Follicular Lymphoma Treated with Rituximab-Containing Regimens

Differential Expression of IL-17 Correlates with Clinical and Pathological Features of ITP

Immunohistochemical Expression of CD123 Is Associated with an Inferior Clinical Outcome in Acute Myeloid Leukemia

Scoring System Using Age, C-Reactive Protein, Hemoglobin, and Albumin (ACHA) For Predicting Outcomes Of Diffuse Large B-Cell Lymphoma In The Rituximab-Era

Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells

Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

Update search

Increased C-Reactive Protein Level Is Associated with Poor Prognosis in Patients with Follicular Lymphoma Treated with Rituximab-Containing Regimens

Differential Expression of IL-17 Correlates with Clinical and Pathological Features of ITP

Immunohistochemical Expression of CD123 Is Associated with an Inferior Clinical Outcome in Acute Myeloid Leukemia

Scoring System Using Age, C-Reactive Protein, Hemoglobin, and Albumin (ACHA) For Predicting Outcomes Of Diffuse Large B-Cell Lymphoma In The Rituximab-Era

Inhibition of Phosphatidylinositol 3-Kinase Is Effective to Suppress the Growth of CD20-Negative Refractory Diffuse Large B-Cell Lymphoma Cells

Treatment Effect of Rituximab Plus Chemotherapy Is Obtained by Improving Survival from Non-Germinal Center-Type Untreated Diffuse Large B-Cell Lymphoma.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only